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Adult stem cells are activated to proliferate and differentiate during normal tissue homeostasis as well as in disease
states and injury. This activation is a vital component in the restoration of function to damaged tissue via either
complete or partial regeneration. When regeneration does not fully occur, reparative processes involving an
overproduction of stromal components ensure the continuity of tissue at the expense of its normal structure and
function, resulting in a “reparative disorder”. Adult stem cells from multiple organs have been identified as being
involved in this process and their role in tissue repair is being investigated. Evidence for the participation of
mesenchymal stromal cells (MSCs) in the tissue repair process across multiple tissues is overwhelming and their role
in reparative disorders is clearly demonstrated, as is the involvement of a number of specific signaling pathways.
Transforming growth factor beta, bone morphogenic protein and Wnt pathways interact to form a complex
signaling network that is critical in regulating the fate choices of both stromal and tissue-specific resident stem cells
(TSCs), determining whether functional regeneration or the formation of scar tissue follows an injury. A growing
understanding of both TSCs, MSCs and the complex cascade of signals regulating both cell populations have,
therefore, emerged as potential therapeutic targets to treat reparative disorders. This review focuses on recent
advances on the role of these cells in skeletal muscle, heart and lung tissues.
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Introduction
Tissue repair post-injury or during disease culminates in
either complete restoration of tissue integrity, defined
here as regeneration, or in a process that leads to the
generation of stromal structures that replace functional
tissue. These structures, while vital in ensuring tissue
continuity, do not support, and in some instances even
interfere with, tissue or organ function. The establish-
ment of these stromal scars is referred herein as “repair”,
and conditions in which they become predominant are
called “reparative disorders”. This term encompasses
diseases or symptoms exhibited during the repair
process of damaged tissues that have been described in
the literature since the early nineteenth century, including
adipocyte accumulation (fatty degeneration), ectopic bone
formation and fibrous tissue deposition [1-3]. In the* Correspondence: fabio@brc.ubc.ca
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distribution, and reproduction in any mediumcontext of mammalian biology, tissue regeneration is an
essential process for restoring structure and function of
traumatized organs. Regeneration of tissues is typically
accompanied by acute or chronic inflammation caused by
the disease or trauma, and involves the coordinated inter-
action among multiple cell types, including tissue specific
stem/ progenitor cells (TSCs), mesenchymal stromal cells
(MSCs) and immune cells. Many of the same cell types
involved in regeneration also contribute to repair, suggest-
ing that aberrant environmental cues and alterations of
the signaling networks between these cells are central to
the establishment of reparative disorders [4].
Several sources have been proposed for the progeni-
tors involved in reparative disorders, including local
sources, such as the damaged tissues themselves, and
systemic sources, such as the bone marrow [5]. Locally,
both tissue specific stem cells and ubiquitous mesenchy-
mal and endothelial progenitors have been implicated inntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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brotic matrix producing cells, adipocytes and osteocytes.
Systemically, a role has been proposed for bone marrow
derived cells reaching the repairing tissues through the
bloodstream. Here, we review the evidence concerning
these different types of stem cells and, in particular, the
role of TSCs and MSCs in reparative disorders. We also
provide an overview of the signaling pathways mediating
their interactions.
The three most commonly occurring outcomes of rep-
arative disorders are fibrosis, fatty degeneration and het-
erotopic ossification. Fibrosis is a defining characteristic
in most reparative disorders and can take place in nearly
every tissue. In fibrosis, damaged structures are grad-
ually replaced by collagen-rich connective tissue
resulting in anatomical anomalies as well as reduced
functional capacities. The poorly defined fibroblast or
myofibroblast, the effector cell components of con-
nective tissue, is thought to be responsible for produ-
cing excess collagen and other extracellular matrix
(ECM) proteins [6]. These same processes, however,
also take place during normal regeneration, and are
likely to be critical for its success. Another type of
common reparative disorder is the accumulation of fat
in damaged tissues leading to “fatty degeneration” and
loss of function [4-6]. Usually, fat is found in newly
formed adipocytes infiltrating the tissue, most often
associated with concurrent fibrotic matrix deposition,
and in these cases it is clearly associated with injuries
and defective repair processes [7-9]. Finally, heteroto-
pic ossification, also known as ectopic bone formation,
is another frequent reparative complication that takes
place in the context of excessive trauma, surgery,
wounds and burns. While non-hereditary and heredi-
tary extra-skeletal bone formation is discussed in detail
elsewhere [10,11], here we will focus only on the
source of osteogenic cells in aberrant repair processes.
Tissue resident stromal cells
In the adult organism, fibroblasts, adipocytes and osteo-
cytes are thought to be generated from the same multi-
potent mesenchymal progenitors. These progenitors,
officially termed mesenchymal stromal cells (MSCs) in a
positional paper from the International Society for Cel-
lular Therapeutics [12] continue to be referred to as
mesenchymal stem cells [13], despite the lack of clear
experimental evidence supporting their ability to self-
renew and satisfy the most basic definition of a stem cell
[14]. The accumulation of these mature cell types in tis-
sues that have failed to properly regenerate suggests that
alterations in the function of MSCs may represent a
common thread underlying reparative disorders [15].
While a minimal set of markers defining an MSC has
been agreed upon [12], expression of these markers isclearly heterogeneous both in vivo and in vitro and does
not currently allow their prospective purification. In
addition, while MSCs retain a similar developmental
potential in most tissues, the expression of specific
markers may vary depending on their specific anatom-
ical location, a reality that has hindered the proper
characterization of stromal progenitors. To date, the
most reliable characteristic of stromal progenitors is
the ability to produce fibroblastic colonies and, under
the appropriate culture conditions, to differentiate in
adipocytes, chondrocytes and osteogenic cells. The gen-
eration of additional cell types, such as endothelium
and skeletal muscle, has been reported, but no consen-
sus exists on whether such expanded developmental
potential is actually observed in physiological condi-
tions. Indeed, in the absence of specific markers to
identify them in situ, elucidating the role of MSCs in
the maintenance of differentiated tissues, such as bone
and fat depots in vivo, has been difficult and their im-
portance is as yet unclear. Another role for this cell
type that has emerged over the years has spurred their
therapeutic exploitation in ex vivo delivery approaches,
and lies in their ability to provide trophic support to
multiple cell types following tissue damage.
Almost all postnatal organs and tissues contain MSCs
[16], and the list of resident stromal cells involved in tis-
sue homeostasis and repair now includes multiple cell
types, such as pericytes in multiple tissues [17,18], fibro-
adipogenic progenitors (FAPs) in muscle and adipose tis-
sues [19,20], adipose precursor cells in skin [21] and
myo-fibroblasts in the liver, kidneys and lungs [22]. It is
unclear whether these are truly distinct cell types, or if
they, rather, represent a diffused stromal progenitor sys-
tem comprised of cells that display different propensity
to spontaneously differentiate along specific lineages, but
possess a common underlying developmental potential
that can be revealed by exposure to the appropriate
stimuli. In addition to these ubiquitous progenitors, tis-
sue fibroblasts have also been proposed to arise from cir-
culating bone marrow cells or, in specific organs, from
epithelial-mesenchymal transition (EMT) (see reviews
[23,24]); the controversial evidence supporting these
claims will be discussed below. The multiple proposed
sources of fibrogenic cells in adult life are schematically
depicted in Figure 1.
Despite the uncertainties and controversies stemming
from their incomplete characterization, recent literature
clearly supports a role for MSCs not only in immuno-
modulation, trophic support, angiogenesis and other
processes associated with successful tissue regeneration,
but also in reparative disorders, such as fibrosis and fatty
degeneration [25-27]. Here we discuss recent advances
on the role of MSCs in skeletal and cardiac muscle as















Figure 1 Potential sources of MSCs in tissue repair. During injury or disease tissue-resident MSCs (mesenchymal stromal/stem cells) can
expand and provide trophic support for regeneration and/or differentiate to produce fibrosis, fatty degeneration or ectopic ossification or a
combination of these. In addition, contribution to the fibrogenic cell pool by circulating “fibrocytes” originated from BM (bone marrow) and
either EMT/EndMT (epithelial-mesenchymal transition/endothelial-mesenchymal transition) are proposed even though their existence, as well as
the impact of their contribution to the deposition of fibrotic matrix, is controversial.
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Skeletal muscle – an ideal regenerative/degenerative model
system
Skeletal muscle, like many other organs, contains stro-
mal cells that are active following injury in both healthy
animals and disease models. In addition, stromal cells
are believed to play an essential role in muscle develop-
ment [28]. These stromal cells are found in the muscle
interstitium as well as associated with blood vessels
(Figure 2). While often found in a perivascular position,
they have been reported not to express typical pericytic
markers, such as NG2 [29,30]. In mice, these cells are
capable of spontaneously differentiating along the fibro-
genic and adipogenic lineages in vitro, and have, therefore,
been provisionally called fibro-adipogenic progenitors
(FAPs) [19]. FAPs can be isolated as CD45-/CD31-/α7
/CD34+/Sca-1+/PDGFRα+ cells. Cells expressing fibroblast
markers (ER-TR7/FSP1/αSMA) or adipogenic markers,
such as perilipin, arise from individual multipotent pro-
genitors contained in this population. We and others
[19,31] have further demonstrated that the fate of theseprogenitors is heavily dependent on the environment
within which they reside. This local microenvironment
dictates whether these cells provide trophic support to
satellite cells, the endogenous myogenic stem cells, to
yield complete regeneration of injured muscle or whether
they generate the components of the fibro-fatty tissue
infiltrates often found in degenerating muscle tissue. A
role for these cells in the efficient regeneration of muscle
is also supported by depletion experiments relaying on the
expression of CRE recombinase under the control of the
transcription factor Tcf4 [28]. This approach led to the de-
pletion of only about 40% of the cells, and highly efficient
deletion of stromal progenitors has yet to be achieved in
any organ. More recently, also in support of a paracrine
effect of MSCs, Lavasani et al. [32] reported that muscle
derived stem/progenitor cells (MDSPCs), essentially stro-
mal cells isolated from young mice, were able to improve
degenerative changes in aged mice and observed a correl-
ation between MDSPC abundance and better muscle fiber
maturation post injury.
Skeletal muscle resident FAPs are quiescent in healthy




Figure 2 Fibro/adipogenic progenitors (FAPs) in skeletal
muscle. Confocal image of a cluster of muscle fibers harvested from
non-damaged muscle showing the relationship between
mesenchymal progenitors expressing nuclear GFP under the control
of the PDGFRα locus and fiber-associated blood vessels positive for
CD31 (red). Nuclei are stained blue.
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space between myofibers, where they presumably carry
out their trophic support function. Following this period
of expansion, and at a time in which myogenic progeni-
tors are differentiating to regenerate myofibers, the ex-
cess FAPs generated during the expansion phase quickly
disappear and the cells return to quiescence. This, how-
ever, is not the case in degenerative disease or during
aging. In situations where regeneration fails, FAPs persist
and generate fibrous/fatty tissue that, while maintaining
structural integrity, hinders function and subsequent re-
generation [33,34]. It is important to note that FAPs
have been reported to be the only source of collagen
producing cells in regenerating skeletal muscle [35],
clearly pointing to these cells as the main origin of fibro-
sis. While strong support exists for both the trophic role
of FAPs and their role on tissue degeneration, the signals
regulating their growth, survival and differentiation are
still unknown. As these signals represent promising
therapeutic targets for the treatment of acute and
chronic injuries, they are the objects of intense investiga-
tion [36].
Role of skeletal muscle derived MSCs in heterotopic
ossification
Heterotopic ossification is a common finding following
severe or repeated soft tissue injuries, usually associated
with fibrotic or fibro-fatty degeneration. The involve-
ment of MSC-like progenitors in this process issupported by observations in war-traumatized patients,
whose muscle are found to contain cells capable of produ-
cing fibroblastic colonies and to give rise to osteoblasts,
adipocytes and/or chondrocytes [37-39]. Presumably in
these instances, while a subset of local mesenchymal pro-
genitors proliferate and differentiate into fibroblasts pro-
ducing fibrotic matrix, some adopt a different lineage
commitment and become osteoprogenitors. They, in turn,
differentiate into osteoblasts, eventually resulting in
ectopic bone formation [40]. Indeed, while FAPs were ori-
ginally described as bipotent progenitors due to their
spontaneous differentiation along the fibrogenic and adi-
pogenic lineages, recent evidence strongly supports their
role in ectopic bone formation. Following this, early
reports suggested that these cells could generate alkaline
phosphatase positive cells [31]. More recently, [41]
reported that CD31–/CD45–/PDGFRa+/Sca-1+/Tie2+ pro-
genitors from skeletal muscle could generate cells expres-
sing the osteoprogenitor marker osterix when exposed to
bone morphogenic protein 2 (BMP2) in vitro or in a trans-
plantation setting. In addition, lineage-tracing experiments
showed that these cells were the main source of ectopic
cartilage and bone when BMP2 was delivered to skeletal
muscle in vivo [41]. In these experiments, not all osteo-
genic cells expressed the Tie2-CRE activated lineage-
tracing marker. However, it is unclear whether this reflects
inefficient CRE mediated recombination or the participa-
tion of Tie2 negative cells in this process. Supporting our
previous results, without addition of BMP2, these cells
failed to adopt the fate of cartilage or bone, demonstrating
that environmental cues are dictating the destiny of these
progenitors and, thereby, the outcome of wound healing.
Role of tissue-specific stem cells in skeletal muscle
degeneration
Although the role of MSCs in the development of rep-
arative disorders in skeletal muscle has been clearly
demonstrated, there is also evidence implicating a role
of TSCs in modulating aberrant repair processes in this
organ. The importance of the principal stem cell in adult
myogenesis, the satellite cell, in regeneration is well
established, but the relationship between these stem cells
and tissue degeneration is much more complex and not
well understood. Satellite cells reside between the myofi-
bers and basement membrane of the muscle bundle [42]
and unlike tissues that experience constant wear and
tear, these TSCs are normally quiescent/stable, and are
not activated until prompted by injury. Quiescent satel-
lite cells are identified by their expression of Pax7, a
paired homeobox transcription factor partly responsible
for survival and specification of the myogenic cell
lineage [43]. Although an excellent marker of all satellite
cells in the wild-type adult, Pax7 is only required dur-
ing the neonatal stage for satellite cell maintenance,
Pretheeban et al. Fibrogenesis & Tissue Repair 2012, 5:20 Page 5 of 12
http://www.fibrogenesis.com/content/5/1/20proliferation and differentiation [44,45]. Following trau-
matic myofiber damage or temporal progression of my-
opathy, these satellite cells become activated and
readily proliferate, differentiate and give rise to myo-
blasts, which fuse with damaged myofibers or form new
myofibers.
Fibrosis is often associated with the impairment of
stem cell populations in tissues, which are observed in
many disease conditions. In skeletal muscle, fibrosis was
considered to be caused by dysfunctional satellite cells.
Using a murine model of muscular dystrophy (MDX),
Alexakis and others reported the expression of collagen
in primary myoblasts [46]. They have also found colla-
gen expression in C2C12, a myoblast cell line. These
findings indicate that satellite cells and transitionally
amplifying myoblasts might deviate from their myogenic
process to lead fibrosis-dominated degeneration. Fur-
thermore, Keller [47] has suggested that the dysregula-
tion of satellite cells during neonatal muscle growth is
linked to rhabdomyosarcoma, a rare form of connective
tissue tumor. Recently, in a mouse model of spinal mus-
cular atrophy, mutation in the survival of motor neuron
(SMN) gene is shown to affect the satellite cell’s intrinsic
differentiation capacity, leading to a reduced efficiency
in myotube formation [48]. Moreover, the conversion of
satellite cells from a myogenic lineage to a fibrogenic
lineage is documented in aging [49] and suggested that
in aged mice, activation of the canonical Wnt signaling
pathway is responsible for a pro-fibrotic phenotype.
Other cases of fibrogenesis in myoblasts are also
reported [50,51]. In addition, a recent study examining
the stem cell function in aged people demonstrates that
an age-related impairment of satellite cells is associated
with increased co-localization of myostatin in satellite
cells of type II myofibers [52]. Thus, tissue-specific stem
cells responsible for regeneration, such as satellite cells
in skeletal muscle, may also be involved in degenerative
processes; however, whether the triggers for degener-
ation are cell autonomous or environmental influences,
such as niche factors, is unknown.
Tissue-resident MSCs reside in the heart
In mammals, cardiac damage is not followed by the
complete replacement of lost cellular components but is
rather defined by a relatively minor capacity for regener-
ation and far more robust reparative response. Lacking
an ability to regenerate, the formation of a scar in a
timely manner following cardiac damage or during car-
diac disease is critical in allowing continued organ func-
tionality. Although there is a growing body of evidence
demonstrating that the heart harbors its own population
of TSCs, the cardiac stem cells [37,38], which account
for the limited regenerative capacity of this organ, recent
evidence has suggested that, similar to other organs, itsrepair processes may be governed by a cardiac-resident
population of MSCs. The identification and elucidation
of developmental origins of a novel population of stromal
progenitors present within the myocardium has recently
been reported [39], and further been demonstrated to be
highly similar to MSCs derived from other tissues [40].
This population of cells contains all the fibroblastic
colony-generating progenitors in the tissue, and was iso-
lated based on markers essentially identical to those
expressed by stromal progenitors in skeletal muscle (Sca-1
+/PDGFRa+/CD31–) and was further shown to originate
from the pro-epicardium. Expression of accepted markers
of MSCs (CD44, CD90, CD29 and CD105) was confirmed
on these cells, which also exhibited long-term growth po-
tential in culture and were reported to possess the ability
to form multiple mesodermal lineages (cardiomyocytes,
endothelium, smooth muscle, adipocytes, cartilage and
bone). As in skeletal muscle, in adult mice these cells
occupy a perivascular, adventitial niche. A wider develop-
mental potential encompassing elements of all germ layers
has been reported for these cells upon co-transplantation
with teratoma-forming ES cells, although the fact that
fusion-induced reprogramming was not excluded in these
experiments is a caveat. While the response of these cells
to acute or chronic damage has yet to be analyzed in de-
tail, it seems likely that similar to their phenotypically
identical counterparts in skeletal muscle and other tissues
[35,53], cardiac Sca1+, PDGFRα+ cells are a main source
of fibrogenic cells in pathological cardiac fibrosis and that
they participate in the formation of post-infarction scars.
Tissue-resident MSCs in the lung
In lungs, an anti-fibrotic role has been reported for ex-
ogenously delivered bone marrow derived MSCs, which
likely rests on their ability to secrete trophic factors dur-
ing normal regeneration. However, in keeping with what
is reported in other tissues, lung derived/resident MSCs
(LR-MSCs) have also been associated with fibrogenesis
and aberrant tissue repair in lung injuries, such as trans-
plantation surgery [54]. Lama and others first isolated
LR-MSCs from the bronchoalveolar lavage fluid of lung
transplantation patients [55]. These cells exhibited
plastic adherence, formation of colony forming unit –
fibroblasts (CFU-Fs), multipotency and expression of a
combination of typical MSC surface markers CD44,
CD73, CD90 and CD105 [55,56]. In most of the studies
in which LR-MSCs exhibited a progressive fibrotic
phenotype, investigators have used chronic injury
models. Studies describing a positive role for exogen-
ous MSCs, however, mainly relied on acute injury
models, supporting the notion that these cells may play
different roles in different settings.
It has been suggested that bi-directional crosstalk be-
tween stromal progenitors and cells involved in immune
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MSCs and vice versa. Jun and others recently characterized
a population of lung-derived stromal cells (Hoechstdim/
CD45-), which attenuated bleomycin-induced lung fibrosis
and modulated local immune function by inhibiting anti-
gen driven proliferative responses of effector T cells and
decreasing the number of lymphocytes and granulocytes in
bronchoalveolar fluid when transplanted [57]. These cells
were distinct from lung fibroblasts in terms of gene expres-
sion, showing decreased expression of genes associated
with inflammation, myofibroblast specification and extra-
cellular matrix production. Unfortunately, as in other tis-
sues, the heterogeneity of methods and markers used for
the definition and characterization of LR-MSCs makes it
very difficult to compare different studies and reach a con-
sensus on their role at this time.
Apoptosis of stromal cells has been proposed to be
one of the main mechanisms leading to the resolution of
fibrosis during normal wound healing in many organs,
and it is believed that in progressive fibrotic lesions,
MSCs and their progeny escape its induction, leading to
increased matrix deposition. Proposed roles of macro-
phages, T cells and the inflammatory microenvironment
in general in regulating the survival of LR-MSCs in air-
way and interstitial pulmonary fibrosis are reviewed else-
where [58].
Alternative cellular sources for tissue-effector
myofibroblasts
The progression from regeneration to repair invariably
involves the development of fibrosis, defined as an ex-
cessive deposition of extracellular matrix. The principal
cell type known to be involved in this process is an acti-
vated fibroblast derivative called a myo-fibroblast. The
transition towards fibrosis was traditionally thought to
involve expansion of stromal progenitors and subsequent
differentiation into myo-fibroblasts, defined by increased
synthesis of ECM proteins, such as fibrillar collagens
and fibronectin as well as de-novo expression of alpha-
smooth muscle actin. Although the importance of myofi-
broblasts in the development of fibrosis is generally
accepted, there continues to be a significant debate
whether alternative cellular sources, rather than differen-
tiation from tissue-resident mesenchymal progenitors,
exist for myofibroblasts.
The notion that collagen-producing myofibroblasts
arise solely from the proliferation and differentiation of
tissue-resident cells began to be questioned in the mid-
1990s when two alternative cellular sources were proposed:
(1) epithelial cells undergoing epithelial-to-mesenchymal
transition (EMT) [59] and (2) circulating bone-marrow
derived fibrocytes [5]. These concepts have important
implications towards both the theoretical cellular processes
underlying the development of fibrosis, and also thedevelopment of novel therapeutics to abrogate the
process. Despite a wealth of literature supporting both
theories, a growing number of recent studies employing
much more rigorous lineage tracing analysis have cast a
significant degree of doubt on the notion that fibro-
genic cells arise from sources outside of tissue-resident
MSCs.
Epithelial-to-mesenchymal transition (EMT)
Long known to be involved in metazoan embryogenesis,
recent studies provided evidence that epithelial mesen-
chymal transition can also occur in adult tissues during
the development of fibrosis as well as the progression
and metastasis of cancer. Although the prevalence, as
well as importance, of EMT in both embryogenesis and
cancer is rarely disputed, a growing body of recent evi-
dence has led many to reject the notion that EMT plays
a role in solid organ regeneration and repair [60-62]. Re-
cent use of more rigorous lineage tracing tools have
strongly called into question the ability of epithelial cells
to transition into collagen-producing mesenchymal cells
during repair processes in numerous tissues, such as the
kidneys [63-65], liver [66-68] and lungs [69]. There is a
growing consensus that although EMT can be achieved
in vitro through transforming growth factor (TGF)β1
treatment, this process does not make any significant
contribution in vivo during tissue repair. Additionally,
research attributing EMT as an important source of
myofibroblasts have widely used the marker FSP1 (also
known as S100A4) as a marker of epithelium-derived
fibroblasts, which has repeatedly been shown to not
label collagen producing cells in some tissues [65] and
to lack specificity by labeling other cells, such as mono-
cytes, macrophages, neutrophils and granulocytes [70].
Such critiques towards the field of EMT in tissue re-
pair can also be applied to other processes, such as
endothelial-to-mesenchymal transition (EndMT), which
has used similarly questionable methods to demonstrate
EndMT as an important source of tissue-effector myofi-
broblasts [71]. Further, additional doubt can be cast on
EMT and EndMT data due to recent reports which dem-
onstrate that Cre drivers previously thought to exclu-
sively label epithelial or endothelial lineages (for example,
Tie2) do not possess the necessary specificity to conclude
that progeny labeled by these markers are exclusively
derived from the epithelium or endothelium [41].
Fibrocytes
Circulating bone marrow derived mesenchymal progeni-
tors, termed fibrocytes, have been proposed as a second
alternative source of collagen-producing myo-fibroblasts
in situations of tissue repair [5]. First described in 1994
[72], fibrocytes have classically been identified using a
combination of hematopoietic markers CD34 and CD45,
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gen 1, although numerous further markers have been
added in recent years [73]. Although there continues to
be numerous studies published describing the role of
circulating cells in the development of fibrosis, a number
of recent reports have begun to call into question this
model. Central to arguments that oppose the role of
fibrocytes in fibrosis has been that much of the data sup-
porting this model is based on phenotypical identifica-
tion of fibroblasts of bone marrow derived origin, rather
than characterization of the functional role these cells
have in the development of tissue fibrosis. Following
this, more recent studies employing more sophisticated
techniques, such as genetic polymorphisms of collagen
proteins in sex mismatched transplant recipients [74], as
well as more specific collagen transgenics [75], have pro-
vided compelling evidence that, in numerous types of
tissue repair, collagen-producing myofibroblasts arise
solely from cells residing within the organ. Additionally,
it should be noted that the same problematic reagents
employed to identify the role of EMT in fibrosis, such as
fibroblast markers of dubious specificity (for example,
FSP1, vimentin) are also prevalent in a number of studies
examining the role of fibrocytes [71].
Signaling in MSCs
Given their relevance in tissue regeneration, MSCs must
maintain fluid communication with their surroundings.
Indeed, a variety of stimuli, including physical and
chemical signals originating in both the niche and the
systemic environment, convey information to the MSCs.
Integration of such signals can result in alteration of the
otherwise quiescent state of MSCs, eliciting a sequence
of fate choices that may include proliferation, self-
renewal, migration, differentiation and cell death. In the
absence of tissue damage and inflammation, systemic
and metabolic cues can modulate the activity of stem
cells under what can be regarded as homeostatic condi-
tions [76]. Upon tissue damage, however, acute signals
become the leading cues directing MSC activity. The
combination of systemic and acute stimuli eventually
drives the fate choice of MSC-derived progenitors into
lineages that will contribute to the regeneration of the
tissue. Under pathological conditions, however, aberrant
signaling can lead to the development of ectopic cell
types that contribute to the degeneration of the damaged
tissue. In addition to the better-characterized pathways,
such as FGF, PDGF and EGF, current advances in the
study of the TGFβ, BMP and Wnt signaling cascades
have disclosed a critical role for these factors in the
regulation of mesenchymal stem cell behavior during
tissue regeneration. The fact that the three pathways
interact closely, partly through shared intracellular
components, provides a number of interesting signalingcrossroads that will be worth exploring in further
depth. A summary of these signaling pathways and
their effects is illustrated in Figure 3.
TGFβ, a member of the TGFβ superfamily, constitutes
one of the major regulators of mesenchymal fate choice
in postnatal life [77]. TGFβ signaling supports the early
stages of chondroblastic and osteoblastic differentiation,
while acting as an inhibitor of the advanced stages of
osteoblast differentiation [78]. TGFβ inhibits adipogenic
differentiation [79] through a route that involves inter-
action between the canonical complex SMAD3/SMAD4
with the transcriptional regulator C/EBP [80].
TGFβ signaling plays a pivotal role in both dermal
homeostasis and hair follicle regeneration, where TGFB2
produced by the dermal papillae of the follicles drives
hair follicle stem cells out of quiescence and activates
them during the telogen-to-anagen transition [81].
Timely TGFβ release is critical for the initial stages of
wound healing. Following damage, TGFβ1, -2 and −3 are
secreted by various cell types, including platelets, fibro-
blasts, macrophages and keratinocytes. TGFβ signaling
stimulates the temporary production of extracellular
matrix (ECM) by fibroblasts and attracts macrophages
that will participate in the inflammatory response [82].
Aberrant TGFβ signaling in the dermis, on the other
hand, elicits excessive ECM deposition, fibrosis and scar
formation that can lead to the formation of skin keloids
[82]. In addition to its effect on fibroblasts and macro-
phages, TGFβ stimulates proliferation and sphere colony
formation in skin-derived precursors (SKPs) in vitro,
without altering their multipotency [83]. Excessive TGFβ
production also correlates with skeletal muscle (SM)
fibrosis [84], a characteristic feature of Duchenne mus-
cular dystrophy [85]. Within SM, TGFβ targets mesen-
chymal Lin-/α7-/Sca-1+/PDGFRa+ progenitor cells that
reside in the interstitial mesenchyme and can differenti-
ate into collagen-producing fibroblasts [35]. Importantly,
the same progenitor population can adopt the adipo-
genic lineage upon SM degenerative damage, leading to
intramuscular ectopic fat accumulation [19,20,31].
The TGFβ family of signaling proteins is also import-
ant in the maintenance and expansion of bone and car-
tilage, largely through BMP proteins and TGFβ itself
[76]. TGFβ promotes the proliferation, early differenti-
ation and lineage commitment of bone progenitors
through Smad2/3 and TAK1-MKK-p38 signaling [78].
Members of the BMP: BMP-2, 4, 5, 6 and 7 constitute
osteogenic inducers. In particular, BMP-2 expression is
sufficient for full osteogenic commitment, and loss of
BMP-2 leads to impaired osteogenesis [86]. BMP-2 sig-
nals through type -I and -II BMP receptors and through
the ALK2 receptor, leading to the activation of the
Smad1/5/8 canonical pathway [87,88]. Following TGFβ
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Figure 3 Signaling pathways driving mesenchymal stem cells to differentiate into lineages found in reparative disorders. While Wnt10b
represses adipogenesis through the activity of B-catenin/TCF/Lef transcriptional complexes, activation of the non-canonical Wnt pathway by
Wnt5b leads to repression of TCF/β-catenin transcriptional activity and yields the opposite results. Non-canonical TGFβ signaling participates in
bone formation through activation of the osteogenesis regulator Runx2. On the other hand, canonical TGFβ signaling plays a central role in the
regulation of the fibrogenic gene program. The BMP signaling pathway drives osteogenesis through SMADs 1, 5, 8 and shares the SMAD4
component with the TGFβ pathway.
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tional regulator that commands the expression of the
osteogenic gene program, via Dlx5 [77]. In addition,
Dlx5 also activates Osterix, a regulator of osteoblast
maturation, independently of Runx2 activation [89].
Importantly, both the TGFβ and the BMP pathways
connect with other signals that participate in bone for-
mation. Components of the TGFβ signaling pathway
interact with components of the pituitary hormone
(PTH), Wnt and fibroblast growth factor (FGF) signaling
pathways [90]. The BMP pathway, on the other hand,
cross-talks with Notch, FGF and Wnt signaling [90].
Aberrant BMP signaling has been linked to heterotopic
ossification, a pathological condition characterized by
bone formation in skeletal muscle and soft tissues [40].Mutations in the regulatory domain of the Alk2 receptor
leading to hyper activation of the BMP signaling path-
way have been shown to mimic the pathophysiology of
fibrodysplasia ossificans progressive (FOP), an extreme
form of heterotopic ossification [91]. Recent advances in
the identification of the cellular substrate of FOP indi-
cate that a muscle-resident Lin-/Sca-1+/PDGFRa+/Tie2+
mesenchymal cell population can also adopt the osteo-
genic lineage upon induction with BMP2 [41]. Consist-
ent with the previously discussed role of Lin-/Sca-
1+/PDGFRa+ cells in SM fibro-fatty degeneration, the
Lin-/Sca-1+/PDGFRa+/Tie2+ cells also generated ectopic
adipocytes in the lesions induced by BMP2 injection [41].
The Wnt family comprises secreted cysteine-rich gly-
copeptides that act in a paracrine and autocrine manner
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a non-canonical B-catenin-independent pathway. MSCs
have been reported to express several Wnt ligands, includ-
ing Wnt2, Wnt4, Wnt5a, Wnt11 and Wnt16, along with
Wnt receptors of the Frizzled (FZD) family FZD2, 3, 4, 5
and 6, and co-receptors including LRP5 and 6. While the
contribution of B-catenin-independent signaling on MSC
activity is poorly understood, B-catenin-dependent signal-
ing has been shown to play an important role in adipo-
genic and osteogenic differentiation of MSCs. Binding of
Wnt to the FZD/LRP receptor complex induces the dis-
sociation of the Axin/APC/GSK3B complex which, in the
absence of Wnt signaling, phosphorylates B-catenin
leading to its ubiquitination and degradation. Upon
stabilization, B-catenin translocates into the nucleus,
where it interacts with transcription factors of the
lymphoid enhancer-binding factor/T-cell-specific factor
(LEF/TCF) to induce the transcription of Wnt-regulated
genes. Wnt molecules participate in adipogenic differenti-
ation via the canonical B-catenin pathway. Wnt10b main-
tains preadipocytes undifferentiated by blocking the
activity of the pro-adipogenic factors C/EBPα and PPARγ
[92,93]. Indeed, transgenic mice overexpressing Wnt10b
under the FABP4 promoter possess less adipose tissue in
regular diet conditions and are resistant to diet-induced
obesity. Those data were confirmed independently by
overexpression of a dominant-negative form of TCF4 that
facilitated adipogenic differentiation. Wnt5 also blocks
PPARγ function, through a mechanism that involves
H3K9 methylation [94]. In contrast to their inhibitory
effect on adipogenesis, Wnt molecules induce osteogenic
differentiation of MSCs. Osteogenic differentiation of
MSCs - via a non-canonical pathway - with concomitant
inhibition of adipogenic mechanisms has been shown to
occur in MSCs [95,96]. The dual role of Wnt5 has also
been shown in vivo, in the above-mentioned FABP4-
WNT10B transgenic mice, in which the reduction in fat
tissue is accompanied by an increase in bone mass, and
reduced bone loss [97]. Altogether, a pivotal role for the
Wnt family can be proposed by which these molecules
regulate the balance between adipogenic vs. osteogenic
lineage in MSCs.
Conclusions
Reparative disorders are commonly accompanied with
tissue injuries and subsequent repair processes. Stem
cells are extremely important for tissue repair either by
differentiating into new cells to replace damaged tissue
(TSCs) or to aid in the regenerative or reparative process
(MSCs). During the past decade, employment of various
isolation and lineage-tracing methods both in vivo and
in vitro has led to the identification of several types of
adult tissue resident stem cells in distinct organs, and of
a phenotypically homogeneous population of stromalprogenitors present in all tissues analyzed and likely to
be the in vivo equivalent of the ill-defined but often
mentioned “mesenchymal stem cell”. However, the draw
back in many studies has been the presence of functional
heterogeneity within stem cell populations, which hin-
ders the generalized characterization or comparison of
these cells across species and tissues to use in thera-
peutic settings. Overcoming this obstacle will likely re-
quire high throughput single cell analysis techniques
that are just starting to be available. Apart from their
well-established role in regeneration, TSCs may also
contribute to fibrosis, fatty degeneration or heterotopic
ossification. To what extent this happens, however, is as
yet unknown, and overwhelming evidence implicates
MSCs as the main culprits for most reparative disorders.
In addition, recent findings fundamentally challenge the
hypothesis that MSCs also derive from EMT or EndMT,
and the existence of circulating fibrocytes, suggesting
that local progenitors are the main cell type involved in
repair. Although MSCs’ participation in reparative disor-
ders is proven, the molecular mechanisms by which they
control the reparative process and regulate other cell
types involved is critical for therapeutic intervention and
in turn alter the fate choices of MSCs during repair.
Promisingly, tissue resident MSCs have the potential to
be included in cell-based therapies to treat reparative
disorders as alternative autologous cell sources. More-
over, TGFβ, BMP and Wnt signaling cascades are con-
sidered as key communication partners with other
known signaling molecules in the regulation of MSCs
and, therefore, viewed as potential therapeutic targets.
To fruitfully deploy modulators of these pathways, how-
ever, the complexity of interaction of MSCs both at
cellular and molecular levels need to be further
elucidated.
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